Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for prevention of exudative AMD (PREVENT)
NCT02140151Phase 2Completed
- Sponsor
- Southern California Desert Retina Consultants
- Start
- Sep 2014
- Primary completion
- Jul 2020
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ranibizumab in age-related macular degeneration (AMD), sponsored by Southern California Desert Retina Consultants. Started Sep 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02140151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140151.